Scisparc Stock Performance
| SPRC Stock | USD 1.36 0.01 0.74% |
The entity has a beta of 1.45, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Scisparc will likely underperform. At this point, Scisparc has a negative expected return of -1.74%. Please make sure to validate Scisparc's day typical price, relative strength index, as well as the relationship between the accumulation distribution and value at risk , to decide if Scisparc performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Scisparc has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain rather sound which may send shares a bit higher in February 2026. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders. ...more
Last Split Factor 1:21 | Last Split Date 2025-07-03 |
1 | Is SciSparc Ltd. stock bottoming out - July 2025 Review Weekly High Potential Alerts - newser.com | 10/14/2025 |
2 | Is SciSparc Ltd. stock entering bullish territory - 2025 Year in Review Stock Portfolio Risk Control - newser.com | 10/28/2025 |
3 | How SciSparc Ltd. stock performs in interest rate cycles - 2025 Trading Recap Intraday High Probability Setup Alerts - newser.com | 11/05/2025 |
4 | How SciSparc Ltd. stock performs in interest rate cycles - July 2025 Recap Growth Focused Stock Reports - newser.com | 11/10/2025 |
5 | SciSparc Neurothera Labs Announces Israeli Patent Application in Collaboration with Clearmind Medicine for Novel Non-Hallucinogenic Neuroplastogen Treatment for... | 11/20/2025 |
6 | Neurothera Labs Signs Non-Binding Term Sheet to Acquire Majority Stake in a Quantum Algorithm Bio Data Analysis Company | 12/02/2025 |
7 | SciSparc Shares Experience Pre-Bell Dip Following Quiet Session - timothysykes.com | 12/05/2025 |
8 | Neurothera Labs Granted Patent by Israeli Patent Office for its Proprietary Opioid-Based Patent Family to Enhance Pain Relief and Reduce Side Effects | 12/30/2025 |
| Begin Period Cash Flow | 2.1 M | |
| Total Cashflows From Investing Activities | -1.6 M |
Scisparc Relative Risk vs. Return Landscape
If you would invest 475.00 in Scisparc on October 3, 2025 and sell it today you would lose (339.00) from holding Scisparc or give up 71.37% of portfolio value over 90 days. Scisparc is currently does not generate positive expected returns and assumes 6.7768% risk (volatility on return distribution) over the 90 days horizon. In different words, 60% of stocks are less volatile than Scisparc, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Scisparc Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Scisparc's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Scisparc, and traders can use it to determine the average amount a Scisparc's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.2573
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | SPRC |
Based on monthly moving average Scisparc is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Scisparc by adding Scisparc to a well-diversified portfolio.
Scisparc Fundamentals Growth
Scisparc Stock prices reflect investors' perceptions of the future prospects and financial health of Scisparc, and Scisparc fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Scisparc Stock performance.
| Return On Equity | -12.81 | ||||
| Return On Asset | -0.99 | ||||
| Operating Margin | (5.70) % | ||||
| Current Valuation | 5.04 M | ||||
| Shares Outstanding | 3.29 M | ||||
| Price To Book | 1.12 X | ||||
| Price To Sales | 3.42 X | ||||
| Revenue | 1.31 M | ||||
| Gross Profit | 506 K | ||||
| EBITDA | (6.97 M) | ||||
| Net Income | (7.47 M) | ||||
| Cash And Equivalents | 6.88 M | ||||
| Cash Per Share | 2.15 X | ||||
| Total Debt | 46 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 5.59 X | ||||
| Book Value Per Share | 15.81 X | ||||
| Cash Flow From Operations | (5.1 M) | ||||
| Earnings Per Share | 350.73 X | ||||
| Market Capitalization | 4.47 M | ||||
| Total Asset | 10.35 M | ||||
| Retained Earnings | (74.97 M) | ||||
| Working Capital | 6.1 M | ||||
About Scisparc Performance
By analyzing Scisparc's fundamental ratios, stakeholders can gain valuable insights into Scisparc's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Scisparc has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Scisparc has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 46.40 | 44.08 | |
| Return On Tangible Assets | (0.81) | (0.86) | |
| Return On Capital Employed | (0.94) | (0.99) | |
| Return On Assets | (0.70) | (0.73) | |
| Return On Equity | (0.89) | (0.93) |
Things to note about Scisparc performance evaluation
Checking the ongoing alerts about Scisparc for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Scisparc help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Scisparc generated a negative expected return over the last 90 days | |
| Scisparc has high historical volatility and very poor performance | |
| Scisparc may become a speculative penny stock | |
| The company reported the previous year's revenue of 1.31 M. Net Loss for the year was (7.47 M) with profit before overhead, payroll, taxes, and interest of 506 K. | |
| Scisparc currently holds about 6.88 M in cash with (5.1 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.15, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 26.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from thenewswire.com: Neurothera Labs Granted Patent by Israeli Patent Office for its Proprietary Opioid-Based Patent Family to Enhance Pain Relief and Reduce Side Effects |
- Analyzing Scisparc's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Scisparc's stock is overvalued or undervalued compared to its peers.
- Examining Scisparc's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Scisparc's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Scisparc's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Scisparc's stock. These opinions can provide insight into Scisparc's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Scisparc Stock analysis
When running Scisparc's price analysis, check to measure Scisparc's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Scisparc is operating at the current time. Most of Scisparc's value examination focuses on studying past and present price action to predict the probability of Scisparc's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Scisparc's price. Additionally, you may evaluate how the addition of Scisparc to your portfolios can decrease your overall portfolio volatility.
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios |